BCL2 and neoplasm: In summary, the current study yielded new evidence that aspirin could inhibit effector T cell function via the TIGIT-BCL2-BAX signaling pathway, reducing IL-10 and TGF-β1 secretion and improving effector T cell function, ultimately contributing to the inhibition of tumor progression.